HRP20211608T1 - Polipeptidi za inhibiranje aktivacije komplementa - Google Patents
Polipeptidi za inhibiranje aktivacije komplementa Download PDFInfo
- Publication number
- HRP20211608T1 HRP20211608T1 HRP20211608TT HRP20211608T HRP20211608T1 HR P20211608 T1 HRP20211608 T1 HR P20211608T1 HR P20211608T T HRP20211608T T HR P20211608TT HR P20211608 T HRP20211608 T HR P20211608T HR P20211608 T1 HRP20211608 T1 HR P20211608T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- fhr1
- scr1
- polypeptide according
- scr2
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 18
- 230000002401 inhibitory effect Effects 0.000 title claims 2
- 230000024203 complement activation Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 6
- 102000016550 Complement Factor H Human genes 0.000 claims 5
- 108010053085 Complement Factor H Proteins 0.000 claims 5
- 108010071253 factor H-related protein 1 Proteins 0.000 claims 5
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 claims 4
- 101150105073 SCR1 gene Proteins 0.000 claims 4
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 claims 4
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 claims 3
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
- 208000029574 C3 glomerulopathy Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000004154 complement system Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000008736 traumatic injury Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
Claims (13)
1. Polipeptid naznačen time što sadrži kratka konsenzusna ponavljanja (SCR) 1 do 4 faktora H (FH), SCR1 i SCR2 proteina 1 povezanog s faktorom H (FHR1) i domenu koja je sposobna vezati se na stanične površine.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što se navedena domena koja se može vezati na stanične površine sastoji od SCR19 i SCR20 od FH.
3. Polipeptid prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time što je navedeni polipeptid multimer, poželjno pri čemu navedeni polipeptid sadrži najmanje jedan dimerizacijski motiv iz SCR1 od FHR1.
4. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je navedeni polipeptid sposoban inhibirati stvaranje TCC (C5b-9), poželjno vezanjem polipeptida na C5b-6.
5. Polipeptid koji ima strukturu A-B-C, naznačen time što A sadrži ili se sastoji od SCR1 i SCR2 iz FHR1, B sadrži ili se sastoji od SCR-ova 1 do 4 iz FH, i C je domena koja se može vezati za stanične površine kako je definirano u bilo kojem od prethodnih zahtjeva, poželjno pri čemu A i B su kondenzirani izravno ili preko poveznice i/ili pri čemu su B i C kondenzirani izravno ili preko poveznice.
6. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se SCR-ovi 1 do 4 od FH sastoje od aminokiselina 19-264 of SEQ ID NO:1.
7. Polipeptid prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se SCR1 i SCR2 od FHR1 sastoje od aminokiselina 22-142 of SEQ ID NO:2.
8. Polipeptid kako je definirano u bilo kojem od prethodnih patentnih zahtjeva za uporabu u liječenju ili prevenciji poremećaja srodnim sa ili povezanim sa sustavom komplementa.
9. Polipeptid za uporabu u skladu s patentnim zahtjevom 8, naznačen time što je navedeni poremećaj srodan sa ili povezan sa sustavom komplementa odabran iz skupine koju čine atipični hemolitičko-uremijski sindrom (aHUS), trombotička mikroangiopatija (TMA), C3 glomerulopatija (C3G), IgA nefropatija, sistemski lupus eritematozni nefritis, odbacivanje transplantata, paroksizmalna noćna hemoglobinurija (PNH), starosna makularna degeneracija (AMD), zarazne bolesti, sepsa, SIRS, traumatska ozljeda, ishemija/reperfuzijsko oštećenje i infarkt miokarda.
10. Nukleinska kiselina naznačena time što kodira polipeptid prema bilo kojem od patentnih zahtjeva 1 do 7.
11. Plazmid ili vektor naznačen time što sadrži nukleinsku kiselinu prema patentnom zahtjevu 10.
12. Stanica naznačena time što sadrži nukleinsku kiselinu prema patentnom zahtjevu 10 ili plazmid ili vektor prema patentnom zahtjevu 11.
13. Postupak proizvodnje polipeptida prema bilo kojem od patentnih zahtjeva 1 do 7 naznačen time što obuhvaća uzgoj stanica prema patentnom zahtjevu 12 u mediju za uzgoj u uvjetima koji dopuštaju ekspresiju polipeptida, te ponovno dobivanje polipeptida iz stanica ili medija za uzgoj.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015016665 | 2015-12-23 | ||
| PCT/EP2016/082614 WO2017109208A1 (en) | 2015-12-23 | 2016-12-23 | Polypeptides for inhibiting complement activation |
| EP16828743.1A EP3394089B1 (en) | 2015-12-23 | 2016-12-23 | Polypeptides for inhibiting complement activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211608T1 true HRP20211608T1 (hr) | 2022-01-21 |
Family
ID=57838331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211608TT HRP20211608T1 (hr) | 2015-12-23 | 2016-12-23 | Polipeptidi za inhibiranje aktivacije komplementa |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10640540B2 (hr) |
| EP (1) | EP3394089B1 (hr) |
| JP (2) | JP6771568B2 (hr) |
| KR (1) | KR20180091097A (hr) |
| CN (1) | CN108699121B (hr) |
| AU (1) | AU2016375183B2 (hr) |
| BR (1) | BR112018012844A2 (hr) |
| CA (1) | CA3009393C (hr) |
| DK (1) | DK3394089T3 (hr) |
| ES (1) | ES2895256T3 (hr) |
| HR (1) | HRP20211608T1 (hr) |
| HU (1) | HUE056019T2 (hr) |
| IL (1) | IL260182B2 (hr) |
| LT (1) | LT3394089T (hr) |
| MX (1) | MX2018007392A (hr) |
| PL (1) | PL3394089T3 (hr) |
| PT (1) | PT3394089T (hr) |
| SI (1) | SI3394089T1 (hr) |
| WO (1) | WO2017109208A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117338782A (zh) | 2017-08-31 | 2024-01-05 | 诺华股份有限公司 | 哌啶基-吲哚衍生物的用途 |
| WO2019051443A1 (en) | 2017-09-11 | 2019-03-14 | Insideoutbio, Inc. | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNOGENICITY OF TUMORS |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| EP3586860A1 (en) * | 2018-06-22 | 2020-01-01 | Universität Ulm | Complement inhibitors and uses thereof |
| DE102018120016B4 (de) * | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0097440B1 (en) * | 1982-06-14 | 1986-09-24 | The Upjohn Company | Method and kit for removing and assaying complement system fragments |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| ZA200807620B (en) * | 2006-03-08 | 2009-12-30 | Archemix Corp | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| CL2008003241A1 (es) | 2007-11-02 | 2009-07-31 | Novartis Ag | Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares |
| ES2940466T3 (es) | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
| EP2473186A4 (en) | 2009-08-31 | 2013-07-10 | Ibc Pharmaceuticals Inc | BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF |
| WO2011156356A1 (en) * | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
| NZ746139A (en) | 2011-04-08 | 2023-11-24 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
| CN102978204B (zh) * | 2011-11-11 | 2018-06-08 | 张康 | Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法 |
| WO2013142362A1 (en) * | 2012-03-19 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Regulator of complement activation and uses thereof |
| FR3015484A1 (fr) | 2013-12-20 | 2015-06-26 | Lab Francais Du Fractionnement | Proteines recombinantes possedant une activite de facteur h |
| US20220009979A1 (en) * | 2018-08-22 | 2022-01-13 | Alexion Pharmaceuticals, Inc. | Fusion proteins and methods of treating complement dysregulation using the same |
| GB2583560A (en) * | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| WO2020232319A1 (en) * | 2019-05-15 | 2020-11-19 | Insideoutbio, Inc. | Modular therapeutics for the treatment of inflammatory diseases and cancer |
| US20210371534A1 (en) * | 2020-06-01 | 2021-12-02 | Musc Foundation For Research Development | Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders |
-
2016
- 2016-12-23 HU HUE16828743A patent/HUE056019T2/hu unknown
- 2016-12-23 DK DK16828743.1T patent/DK3394089T3/da active
- 2016-12-23 CA CA3009393A patent/CA3009393C/en active Active
- 2016-12-23 MX MX2018007392A patent/MX2018007392A/es unknown
- 2016-12-23 PL PL16828743T patent/PL3394089T3/pl unknown
- 2016-12-23 SI SI201631377T patent/SI3394089T1/sl unknown
- 2016-12-23 AU AU2016375183A patent/AU2016375183B2/en active Active
- 2016-12-23 US US16/065,272 patent/US10640540B2/en active Active
- 2016-12-23 EP EP16828743.1A patent/EP3394089B1/en active Active
- 2016-12-23 JP JP2018533148A patent/JP6771568B2/ja active Active
- 2016-12-23 LT LTEPPCT/EP2016/082614T patent/LT3394089T/lt unknown
- 2016-12-23 CN CN201680075659.0A patent/CN108699121B/zh active Active
- 2016-12-23 BR BR112018012844A patent/BR112018012844A2/pt active Search and Examination
- 2016-12-23 WO PCT/EP2016/082614 patent/WO2017109208A1/en active Application Filing
- 2016-12-23 IL IL260182A patent/IL260182B2/en unknown
- 2016-12-23 ES ES16828743T patent/ES2895256T3/es active Active
- 2016-12-23 KR KR1020187020929A patent/KR20180091097A/ko not_active Application Discontinuation
- 2016-12-23 PT PT168287431T patent/PT3394089T/pt unknown
- 2016-12-23 HR HRP20211608TT patent/HRP20211608T1/hr unknown
-
2020
- 2020-03-20 US US16/825,711 patent/US11591378B2/en active Active
- 2020-05-01 JP JP2020081070A patent/JP2020167999A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL260182A (en) | 2018-07-31 |
| IL260182B2 (en) | 2023-12-01 |
| IL260182B1 (en) | 2023-08-01 |
| CN108699121B (zh) | 2023-07-04 |
| LT3394089T (lt) | 2021-11-25 |
| JP2019508022A (ja) | 2019-03-28 |
| DK3394089T3 (da) | 2021-11-01 |
| US11591378B2 (en) | 2023-02-28 |
| AU2016375183B2 (en) | 2021-01-21 |
| JP2020167999A (ja) | 2020-10-15 |
| WO2017109208A1 (en) | 2017-06-29 |
| AU2016375183A1 (en) | 2018-07-19 |
| EP3394089A1 (en) | 2018-10-31 |
| PL3394089T3 (pl) | 2022-01-17 |
| EP3394089B1 (en) | 2021-07-28 |
| CA3009393C (en) | 2023-08-22 |
| CA3009393A1 (en) | 2017-06-29 |
| CN108699121A (zh) | 2018-10-23 |
| HUE056019T2 (hu) | 2022-01-28 |
| KR20180091097A (ko) | 2018-08-14 |
| SI3394089T1 (sl) | 2021-12-31 |
| JP6771568B2 (ja) | 2020-10-21 |
| US10640540B2 (en) | 2020-05-05 |
| BR112018012844A2 (pt) | 2018-12-04 |
| ES2895256T3 (es) | 2022-02-18 |
| PT3394089T (pt) | 2021-11-03 |
| US20190300589A1 (en) | 2019-10-03 |
| US20200277347A1 (en) | 2020-09-03 |
| MX2018007392A (es) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211608T1 (hr) | Polipeptidi za inhibiranje aktivacije komplementa | |
| HRP20201160T1 (hr) | Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže | |
| HRP20211934T1 (hr) | Protutijela anti-c5 i postupci uporabe | |
| JP2016026149A5 (hr) | ||
| JP2015532654A5 (hr) | ||
| JP2015134796A5 (hr) | ||
| JP2011097941A5 (hr) | ||
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| IL309801A (en) | Use of protein domains interacting with the nucleosome to enhance targeted genome modification | |
| WO2018022574A3 (en) | Induced expression in plant | |
| JP2017538401A5 (hr) | ||
| PH12018501317A1 (en) | Compositions and methods for efficient targeting of transgenes | |
| HRP20210734T1 (hr) | Koštani morfogenetski proteini | |
| Himeno et al. | Identification of enterocin NKR-5-3C, a novel class IIa bacteriocin produced by a multiple bacteriocin producer, Enterococcus faecium NKR-5-3 | |
| WO2015088937A8 (en) | Axmi477, axmi482, axmi486 and axmi525 toxin genes from bacillus thuringiensis and methods for their use | |
| HRP20191511T1 (hr) | Tatk-cdkl5 fuzijski proteini, pripravci, formulacije i njihova uporaba | |
| PH12018501466A1 (en) | Plants having enhanced tolerance to insect pests and related constructs and methods involving insect tolerance genes | |
| PH12017500020A1 (en) | Plants having enhanced tolerance to insect pests and related constructs and methods involving insect tolerance genes | |
| HRP20200471T1 (hr) | Tonoplastni protonsko/šećerni antiporterski proteini i njihova upotreba u povećavanju koncentracije saharoze u biljnom organu za skladištenje saharoze | |
| CN106471121A8 (zh) | 减少功能蛋白的水平基因转移 | |
| HRP20210823T1 (hr) | Varijante protutijela | |
| WO2013192277A3 (en) | Constructs and methods involving genes encoding glutamate receptor polypeptides | |
| PH12018500191A1 (en) | Novel microorganisms and their use in agriculture | |
| JP2015536347A5 (hr) | ||
| HRP20161615T1 (hr) | Endoglukanaze s poboljšanim svojstvima |